The transaction is subject to certain closing conditions and is expected to close in the next few months.
The transaction does not involve Catalent's Clinical Supply Services operations in Philadelphia, or the blow/fill/seal business in Woodstock. It also does not involve any commercial packaging activity that Catalent conducts outside North America.
Catalent's decision to sell its U.S. commercial packaging operations is based on the company's business strategy to focus on growing its businesses in development solutions and advanced delivery technologies, clinical trial supplies, advanced blow/fill/seal aseptic delivery technology for respiratory, ophthalmic, and other products, as well as offering integrated solutions for the development and supply of injectable biologics and complex pharmaceutical products.
The transaction does not involve Catalent's Clinical Supply Services operations in Philadelphia, or the blow/fill/seal business in Woodstock. It also does not involve any commercial packaging activity that Catalent conducts outside North America.
Catalent's decision to sell its U.S. commercial packaging operations is based on the company's business strategy to focus on growing its businesses in development solutions and advanced delivery technologies, clinical trial supplies, advanced blow/fill/seal aseptic delivery technology for respiratory, ophthalmic, and other products, as well as offering integrated solutions for the development and supply of injectable biologics and complex pharmaceutical products.
Companies in this article
